|
Board
of Directors
Robert
Alonso, President & CEO, Yaupon Therapeutics, Inc. is a seasoned executive with 15 years of domestic and
international pharmaceutical experience in licensing, drug development
and marketing. He has held management positions for large multi-nationals
such as Merck and Hofmann La Roche as well as biotech start-ups with
Layton Bioscience. Mr. Alonso has run a $200 million infectious disease
franchise and he has closed over 15 licensing deals. Mr. Alonso has an
MBA from F.W. Olin Graduate School at Babson College.
David
Drahms - Vice President, Osage Ventures David
began his career at Teradyne, Inc., a Boston-based manufacturer of
semiconductor test equipment, where he was a mechanical engineer before
becoming a project manager. He then attended The Wharton School, where he
graduated with an MBA in Entrepreneurship. While at Wharton, David spent
the summer as an internal strategist with Rohm and Haas, traveled to Peru
to advise a consumer textiles company on a US market entry strategy, and
consulted with Teach for America on how to optimize their recruitment process.
David serves on the Board of Directors for Red Lasso and is a board
observer of Melior Discovery and HardMetrics.
Bill
Hamilton, PhD. - Ralph Landau Professor of Management and Technology
Dr.
Hamilton has served on the University of Pennsylvania faculty since 1967
and is the Landau Professor of Management and Technology and the Director
of the Jerome Fisher Program in Management and Technology at The Wharton
School and the School of Engineering and Applied Science. He also serves
as a director of the following life-sciences companies: Neose Technology,
Inc. (Nasdaq: NTEC ), NovaDel Pharma, Inc. (Amex: NVD) and Neuronyx (a
privately-held leader in stem cell technologies), and previously served
as a Director of Centocor, Inc. prior to its acquisition by Johnson &
Johnson. Dr. Hamilton received his B.S., M.S. (chemical engineering) and
M.B.A. from the University of Pennsylvania and his Ph.D. in applied
economics from the London School of Economics
James
Huang - Entrepreneur in Residence, Vivo Ventures With 20 years of experience in the pharmaceutical
industry, James joined Vivo Ventures from Anesiva, where he has served as
president since September 2005. He joined Anesiva from Tularik Inc.,
where he held the position of vice president of business development and
commercial operations. Prior to Tularik, Mr. Huang was product director
of Avandia and diabetes at SmithKline Beecham PLC (now GlaxoSmithKline)
where he launched Avandia. Mr. Huang also held various positions in
Bristol-Myers Squibb's Worldwide Strategic Product Planning, Managed Care
and Sales and Marketing organizations, and research and development
positions at Alza Corporation. James received an M.B.A. from Stanford
Graduate School of Business and earned a B.S. degree in Chemical
Engineering at the University of California, Berkeley.
Greg
Vontz, CEO, Topica Pharmaceuticals Greg
Vontz brings over 20 years of experience in biopharmaceutical industry.
He began his career with Merck & Company and then spent 12 years with
Genentech, Inc. leading their cardiovascular franchise through 1999.
Following Genentech, Mr. Vontz spent seven years at Connetics, Inc. a
public specialty pharmaceutical company focused on dermatology, where his
most recent role was as President & Chief Operating Officer prior to
the company s acquisition in late 2006 by Stiefel Laboratories. During
his time at Connetics, Greg was responsible for Sales & Marketing,
Research, Development, Manufacturing, Regulatory, Quality and Human
Resources with over 350 total personnel under management. In addition to
his operating experience, Mr. Vontz has also served as director of a
public company, most recently for Adeza Biomedical.
Investors
Ben Franklin Technology Partners of
Southeastern Pennsylvaniaa
Since
1982, Ben Franklin Technology Partners of Southeastern Pennsylvania has
helped grow the region through science, technology, and entrepreneurship.
Part of a statewide network in Pennsylvania funded by the Commonwealth’s
Department of Community and Economic Development, BFTP/SEP has provided
more than $110 million to over 1,400 regional enterprises through various
funding means.
www.sep.benfranklin.org
BioAdvance Greenhouse Fund
BioAdvance
is a venture fund founded with $33.8 million from tobacco settlement
monies to grow the life sciences industry in Southeastern Pennsylvania.
To fulfill its mission, BioAdvance invests in emerging life sciences
technologies with the most promising commercialization prospects.
www.bioadvance.com
Osage Ventures
Osage
Ventures is a venture capital fund that seeks to invest in determined and
creative entrepreneurs that have a unique concept or product. Osage works
closely to mentor entrepreneurs and assists them in building businesses
from ideas. Building value is of primary importance to Osage, and we will
invest the necessary time and capital to grow a business, irrespective of
the future exit date. To date, Osage has seeded companies across a broad
range of industries, many of which became publicly traded entities.
http://osageventures.com/
Palo Alto Venture Investors, LLC
Palo
Alto Investors, LLC (located in Palo Alto, California) is a registered
investment advisor providing investment advisory services to a variety of
investors including individuals, trusts, foundations and institutions.
The firm currently manages over $1.6 billion in assets with a emphasis on
Micro Cap and Small Cap market segments as well as the Healthcare, Energy
and Technology sectors.
http://www.pa-investors.com/
TDH / Midcoast Capital
TDH
is a family of venture capital funds that has been active in the
investment community for more than 28 years, investing over $80 million
in that time. During that time, TDH has invested in dozens of corporate
entrepreneurial situations, all with an eye toward supporting high growth
companies and achieving venture returns for TDH’s investors. ESPN,
Airgas, Intelligent Electronics, Staples and Animas are just a few of its
noteworthy investments.
Vivo Ventures
Vivo
Ventures is a life-sciences focused venture capital firm formed in 1996
with over $650M under management. Vivo Ventures is currently making
investments from its $275M sixth fund into promising biotechnology and
life science companies. With over 90 years of scientific and operational
expertise in biotechnology, Vivo makes investment decisions for the Funds
and helps its portfolio companies develop corporate strategy, arrange
licensing agreements and strategic alliances, recruit key management
personnel, and acquire new products and technology to accelerate growth.
Its current portfolio includes more than 60 private and public
biotechnology companies in the areas of biopharmaceuticals, specialty
pharmaceuticals, and medical devices.
http://vivoventures.com/
|
